A war-linked pharma cost shock is now rippling into India’s healthcare market. Vizag chemists say paracetamol and other essential generics may see hikes of 30–40% as manufacturers face surging raw material prices, especially from West Asia. Current supplies are said to be stable, but future revisions could raise retail bills. The government is working to curb volatility and maintain availability.
Drugmaker Granules says it will tighten internal oversight following a warning from the US FDA. The company, one of the world’s biggest paracetamol makers and a key active pharmaceutical ingredients player, earns a large share of revenue from the United States—making compliance scrutiny especially consequential for future supply and sales.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
